This site is intended for healthcare professionals outside the U.S.
ESTEEM® 1 study. Full analysis set, data as observed. Includes patients with baseline DLQI total score >5.
P < 0.001.
BL, baseline; DLQI, dermatology life quality index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; QoL, quality of life.
Reference: 1. Thaçi D, Kimball A, Foley P, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol. 2017;31(3):498-506.
Please choose a country